Login to Your Account



Tocagen files to raise up to $86.3M for glioma and cancer candidates

By Michael Fitzhugh
Staff Writer

Friday, March 10, 2017

San Diego-based brain cancer therapy developer Tocagen Inc. filed to raise gross proceeds of up to $86.3 million in an IPO intended to help advance its FDA breakthrough-designated candidates, Toca 511 and Toca FC, currently part of a phase II/III trial.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription